Prevalence and predictors of psychological distress among women with ovarian cancer
Prevalence and predictors of psychological distress among women with ovarian cancer
复制标题
DOI：
10.1200/jco.2004.07.028
复制
发表时间：
2004-03-01
影响因子：
45.3
通讯作者：
Bergman, C
中科院分区：
文献类型：
--
作者：
Norton, TR;Manne, SL;Bergman, C
目的确定卵巢癌妇女的心理困扰的患病率，并研究这些困扰的症状和人口统计学和医疗variables.Patients and Methods参与者之间的关联143名卵巢癌妇女。48%的参与者被诊断为晚期疾病（III或IV期），大多数（80%）目前正在接受治疗。心理困扰进行了评估与以下措施：贝克抑郁症量表，心理健康量表，事件的影响规模，和一份问卷调查关于心理健康service use.Results约五分之一的妇女报告中度至重度的困扰，超过一半的报告高压力反应，他们的癌症和治疗。大多数参与者（60%）没有使用任何心理健康服务或精神药物。也有证据表明，年轻的患者，更先进的或复发性疾病的患者，谁最近被诊断为卵巢癌的患者经历了更大的心理distress.Conclusion这些研究结果表明，心理困扰和高压力反应的癌症是普遍存在的女性卵巢癌，这表明他们应该仔细评估，以确定是否治疗这些症状是值得的。(C)2004年，美国临床肿瘤学会。
Purpose To identify the prevalence of psychological distress among women with ovarian cancer and to examine the association between these symptoms of distress and demographic and medical variables.Patients and Methods Participants were 143 women with ovarian cancer. Forty-eight percent of participants had been diagnosed with advanced-stage disease (stage III or IV) and most (80%) were currently receiving treatment. Psychological distress was assessed with the following measures: the Beck Depression Inventory, the Mental Health Inventory, the Impact of Events Scale, and a questionnaire regarding mental health service use.Results Approximately one fifth of women reported moderate to severe levels of distress, and more than half reported high stress responses to their cancer and its treatment. Most participants (60%) were not using any mental health services or psychotropic medications. There was also evidence to suggest that younger patients, patients with more advanced or recurrent disease, and patients who had more recently been diagnosed with ovarian cancer experienced greater psychological distress.Conclusion These findings indicate that psychological distress and high stress responses to cancer are prevalent among women with ovarian cancer, suggesting they should be carefully evaluated to determine whether treatment for these symptoms is warranted.(C) 2004 by American Society of Clinical Oncology.